Candel Therapeutics, Inc. CADL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.84M-10.8% | $11.03M+30.3% | $8.46M+21.0% | $6.99M+74.1% | $4.02M-16.6% | ||
| $6.44M+36.4% | $4.72M-0.5% | $4.75M+13.4% | $4.19M+1.8% | $4.11M+23.8% | ||
| $16.28M+3.4% | $15.75M+19.3% | $13.21M+18.2% | $11.18M+37.5% | $8.13M-0.1% | ||
| -$16.28M-3.4% | -$15.75M-19.3% | -$13.21M-18.2% | -$11.18M-37.5% | -$8.13M+0.1% | ||
| $1.56M+10.5% | $1.42M+780% | $161K-31.8% | $236K-22.9% | $306K-21.5% | ||
| $7.42M— | —— | $1.94M-69.6% | $6.38M-58.9% | $15.51M+361% | ||
| -$8.86M+70.0% | -$29.5M-162% | -$11.27M-135% | -$4.8M-165% | $7.38M+152% | ||
| -$0.14+74.5% | -$0.55-162% | -$0.21-133% | -$0.09-169% | $0.13+133% | ||
| -$16.14M-3.5% | -$15.59M-19.9% | -$13.01M-18.5% | -$10.98M-39.2% | -$7.89M+0.1% | ||
| -$16.28M-3.4% | -$15.75M-19.3% | -$13.21M-18.2% | -$11.18M-37.5% | -$8.13M+0.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Candel Therapeutics, Inc.'s revenue?
- Candel Therapeutics, Inc. (CADL) generated $124.0K in revenue over the trailing twelve months.
- Is Candel Therapeutics, Inc. profitable?
- Candel Therapeutics, Inc. is not currently profitable: it reported a net loss of $54.4M over the trailing twelve months, a -15156.5% net margin.
- What is Candel Therapeutics, Inc.'s earnings per share?
- Candel Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.99.
- Where does Candel Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
